HIV Infections Clinical Trial
Official title:
A Randomized Controlled Trial of a Mindfulness-Based Stress Reduction Intervention for Men Living With HIV
| Verified date | September 2007 |
| Source | Mount Sinai Hospital, Canada |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | Canada: Ethics Review Committee |
| Study type | Interventional |
This study will examine the effectiveness of Mindfulness-Based Stress Reduction (MBSR) in
helping men living with HIV cope with negative emotions and stresses in their life. MBSR is
an approach to reducing stress for patients with chronic medical conditions. It involves
systematic training in mindfulness meditation practices to increase quality of life and to
reduce general stress, anxiety, depression or pain. The effectiveness of MBSR will be
evaluated by looking at changes in participants' experience of stress, anxiety associated
with pain management and psychosocial functioning before and after they receive the MBSR
compared with participants who do not receive the MBSR treatment.
In order to participate, individuals must be: male, living with HIV, age 18-70 years, live
within one hour of participating centre, and have a good understanding of the English
language. Questionnaires will be completed before individuals begin the program, at the end
of the intensive phase (8 weeks) and at 6 months after the start of the group program. The
primary program evaluation outcome will be a reduction in stress; secondary evaluation
outcomes will include the improvements in the physical and emotional experience of pain as
well as general psychosocial functioning and self-esteem.
| Status | Completed |
| Enrollment | 117 |
| Est. completion date | December 2006 |
| Est. primary completion date | |
| Accepts healthy volunteers | No |
| Gender | Male |
| Age group | 18 Years to 70 Years |
| Eligibility |
Inclusion Criteria: - Male - Living with HIV - 18-70 years of age - Fluent in English - Lives within one hour of the hospital Exclusion Criteria: - Severe depression - Current suicide ideation - Substance abuse - Impaired cognitive function |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Country | Name | City | State |
|---|---|---|---|
| Canada | Mount Sinai Hospital | Toronto | Ontario |
| Lead Sponsor | Collaborator |
|---|---|
| Mount Sinai Hospital, Canada | Canadian Foundation for AIDS Research (CANFAR), Samuel Lunenfeld Research Institute, Mount Sinai Hospital |
Canada,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Subjects in the MBSR group will have greater improvement in measures of psychosocial functioning (i.e. anxiety, depression, HIV-related distress, affectivity) at 8 weeks and 6-months post-intervention | 8 weeks and 6 months after start of intervention | ||
| Primary | Subjects in the MBSR group will demonstrate significantly greater improvement on measures of worry and rumination at 8 weeks and 6-months post-intervention | 8 weeks and 6 months after start of intervention | ||
| Primary | MBSR will result in greater improvement in pain compared to the control arm | 8 weeks and 6 months after start of intervention | ||
| Secondary | Reductions in anxiety and depression during MBSR will be moderated by reductions in worry and ruminations, respectively | 8 weeks and 6 months after start of intervention |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
| Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
| Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
| Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
| Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
| Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
| Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
| Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
| Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
| Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
| Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
| Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
| Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
| Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
| Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
| Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
| Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
| Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
| Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
| Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |